| Autor: |
Rothman RB; Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, PO Box 5180, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA. rrothman@mail.nih.gov, Blough BE, Baumann MH |
| Jazyk: |
angličtina |
| Zdroj: |
Trends in pharmacological sciences [Trends Pharmacol Sci] 2006 Dec; Vol. 27 (12), pp. 612-8. Date of Electronic Publication: 2006 Oct 23. |
| DOI: |
10.1016/j.tips.2006.10.006 |
| Abstrakt: |
Biogenic amine transporters (BATs) are integral membrane proteins that translocate biogenic amine neurotransmitters [norepinephrine, dopamine (DA) and 5-hydroxytryptamine (5-HT)] across cell membranes. BATs are the principal sites of action for many psychotropic drugs, including abused stimulants such as cocaine and methamphetamine. Preclinical and human data demonstrate that withdrawal from long-term cocaine administration produces a dual deficit of synaptic DA and 5-HT in the brain, indicating the advantage of developing medications that normalize impairments in both neurotransmitter systems. In this article, we review data supporting the notion that stimulant effects normally produced by increased levels of extracellular DA can be antagonized by concurrent increases in levels of extracellular 5-HT. Accordingly, nonselective BAT substrates that can release both DA and 5-HT, such as the novel compound PAL287, have low abuse potential while maintaining the ability to suppress drug-seeking behavior. The collective findings indicate that such drugs will provide neurochemical normalization therapy for cocaine addiction and might also be useful for treating depression, obsessive-compulsive disorder, attention deficit disorder and obesity. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect